AstraZeneca after ok Ema: “Vaccine safety priority”


AstraZeneca “will continue to work closely with health authorities to ensure appropriate use of the Covid-19 vaccine.” This was stated by the Anglo-Swedish pharmaceutical company in a statement released after the green light of Ema, the European drug agency, for the administration of the product.

Read also

“The company – continues the AstraZeneca note – recognizes and will implement the recommendations of the Prac (the Pharmacovigilance Risk Assessment Committee of the EMA, ed), including the updating of product information, continuing to understand the nature and relevance of these events to ensure that the safe administration of the vaccine continues during this public health crisis. ”

The analysis of the database relating to “tens of millions” of administrations, says the company, “has not shown that these events occur in a more common way than might be expected on millions of people”.

“There is no increase in the general risk of thrombosis with Astrazeneca’s Covid-19 vaccine”, the company remarks in the statement recalling the conclusions expressed today by the EMA. Furthermore, AstraZeneca points out, the EMA concluded that for “each rare case” of thrombosis “the link with the vaccine is not proven”, even if “it is possible and deserves further analysis”. Furthermore, the company notes, “there is no evidence of a problem related to specific batches of the vaccine or to a particular production site”.

“Vaccine safety is a top priority and we welcome the decision by regulators that says the tremendous benefits of our vaccine in stopping the pandemic,” says Ann Taylor, AstraZeneca’s chief medical officer. “We are confident – he concludes – that after the careful decisions of the regulators, vaccinations will be able to resume again throughout Europe”.


Leave a Comment

This site uses Akismet to reduce spam. Learn how your comment data is processed.

Recent News

Editor's Pick